Why Design Therapeutics, Inc.’s (DSGN) Stock Is Up 5.64%
As of Friday, November 06, Design Therapeutics, Inc.’s DSGN share price has surged by 5.64%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Michael Rose
Jenna Brashear
Rosalio Madrigal
| Share Statistics | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $635.2 | $202.9 | 41% |
|
| Shares Out (Mil) | 63.0 | 55.4 | 52% |
|
| Institutional Ownership | 83.6% | 92.9% | 51% |
|
| Float (Mil) | 37.6 | 40.7 | 40% |
|
| Beta | 1.75 | 1.04 | 88% |
|
| Avg Daily Volume (000s) | 377 | 566 | 53% |
|
| Price Change (52-week) |
40.5% | 41.0% | 83% |
|
| Growth | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (53.1%) | (10.3%) | 6% |
|
| EPS (5yr) | (18.4%) | 15.8% | 15 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (21.7%) | (15.7%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 7 | 8 | |
| Current EPS | ($0.395) | ($1.340) | ($1.555) | |
| Month Ago EPS | ($0.388) | ($1.348) | ($1.619) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.396) | ($1.363) | ($1.593) | |
| Year/Year Chg | 22.7% | 10.1% | 53.7% | |
| Financials | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($74) | ($44) | 13% |
|
| EPS (TTM) | ($1.206) | ($1.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $0 | ($1) | 46% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $448 | $144 | 34% |
|
| Valuation | DSGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.13 | 1.97 | 70% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (34.6%) | (47.4%) | 15% |
|
| ROE | (36.9%) | (53.5%) | 18% |
|
| Liabilities to Assets | 6.7% | 29.7% | 4% |
|
| F-Score | 1 | 3 | 1% |
|
Design Therapeutics, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors